Associated tags: FDA, Research, Medical Devices, Biotechnology, Health, Science, Oncology, Surgery, CHCP, Clinical trial, Plasma, Cancer, Cell death, Safety, Patient, FACS, Education minister, MD, Medical device, Immunotherapy
Locations: MASSACHUSETTS, UNITED STATES, NORTH AMERICA, MARYLAND, USA, CHICAGO, ISRAEL, IL
Research,
Robotics,
Oncology,
Medical Devices,
Technology,
Artificial Intelligence,
Clinical Trials,
Science,
Surgery,
Biotechnology,
FDA,
Health,
Risk,
Innovation system,
Doctor of Philosophy,
SMC,
RNS,
Sheba Medical Center,
Medicine,
RMC,
Oncology nursing,
Purdue University,
Canady,
ROS,
Surgical oncology,
Entrepreneurship,
Plasma,
Johns Hopkins University,
Patient,
Multi,
Argon,
Safety,
George Washington University,
Microsoft Access,
Cell death,
Survival,
IDE,
University of Massachusetts,
Treatment,
Multimedia,
Reactive nitrogen species,
Engineer,
CHCP,
University,
Apoptosis,
FACS,
Field line,
Airline,
Rush University Medical Center,
Reactive oxygen species,
Nursing US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.
Key Points:
- US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.
- The CHCP system consists of the Canady Helios Cold Plasma XL-1000 CP Smart Electrosurgical Generator, Canady Helios Cold Plasma Ablators, Foot Pedal and Trolley Cart.
- The Canady Helios Cold Plasma™ System introduces a novel approach to soft tissue ablation using plasma.
- For more information on US Medical Innovation’s products and technology please visit: www.usmedinnovations.com .
Retrieved on:
Friday, September 22, 2023
Research,
Technology,
Medical Devices,
Clinical Trials,
Biotechnology,
Health,
Robotics,
Science,
Oncology,
Artificial Intelligence,
Radiation,
GOOGLE,
Freedom,
Use,
Controller,
CAP,
Female gendering of AI technologies,
Endoscopy,
Recognition,
Intelligence,
Multimedia,
Immunotherapy,
Doctor of Philosophy,
Scientist,
SIRI,
Clinical trial,
Motorized,
MD,
System,
Intel Extreme Masters,
Education minister,
FACS,
Artificial intelligence,
Patient,
Oncology nursing,
FDA,
Recurrence,
Safety,
SMART,
Medical device,
Laparoscopy The Canady Robotic AI Surgical System is the world’s first AI robotic system that delivers cold atmospheric plasma (CAP) which is a three-dimensional non-contact bioelectric pulse electromagnetic field.
Key Points:
- The Canady Robotic AI Surgical System is the world’s first AI robotic system that delivers cold atmospheric plasma (CAP) which is a three-dimensional non-contact bioelectric pulse electromagnetic field.
- The Canady Robotic AI Surgical System will be displayed at the First Global Surgical Oncology Summit in Jerusalem, Israel (January 30 to February 2, 2024).
- View the full release here: https://www.businesswire.com/news/home/20230922283953/en/
Canady Robotic AI Surgical System (Photo: Business Wire)
The Canady Robotic AI Surgical System’s key components are a Motorized Positioning Arm, Speech Recognition Canady Electrosurgical Generator known as ORLI™, Controller for CAP Devices, Robotic Assisted End Effectors which can be used in Open, Laparoscopic, Thoracoscopic, Endoscopic and Mini-invasive surgical procedures.
- Taisen Zhuang, PhD, Chief Technology Officer stated, “The Canady Robotic AI Surgical System sets a new precedent for Robotic Cancer Surgery by combining AI Technology and CAP.
Retrieved on:
Wednesday, August 2, 2023
Research,
Technology,
Medical Devices,
Surgery,
Health Technology,
Biotechnology,
Robotics,
Health,
Science,
Oncology,
Canady,
Cell death,
RNS,
Histone,
Survival,
Clinical trial,
Immunotherapy,
CHCP,
Irreversible electroporation,
Plasma,
ROS,
Cancer,
LRR,
Patient,
Sheba Medical Center,
Reactive oxygen species,
Apoptosis,
Education minister,
Cell division,
FACS,
Neoplasm,
Rush University Medical Center,
Recurrence,
FDA,
Reactive nitrogen species,
Messenger,
Pharmaceutical industry It is estimated that 65% of solid tumor resections result in residual microscopic tumor cells at the surgical margin, which contributes to LRR and poor survival rates.
Key Points:
- It is estimated that 65% of solid tumor resections result in residual microscopic tumor cells at the surgical margin, which contributes to LRR and poor survival rates.
- The recent trial reveals that treating the surgical margin following a tumorectomy significantly reduced local recurrence and increased overall survival.
- CHCP opens a new and promising treatment for addressing the challenges of eradicating microscopic residual cancer cells following surgical tumor resection.
- Jerome Canady, M.D., FACS, CEO stated, “We are very pleased to have our results published in the peer reviewed journal 'Cancers'.
Biotechnology,
Technology,
FDA,
Health,
Oncology,
Robotics,
Health Technology,
Medical Devices,
Research,
Surgery,
Science,
Surgeon,
Freedom,
Rotation,
Medical Innovation Bill,
Food,
Electrosurgery,
Movement,
Flex,
Biomedicine,
MD,
Risk,
FACS,
Dissection,
Dentistry,
Medical device The Canady Flex RoboWrist (Flex RoboWrist) is a fully articulating motorized, 5mm hand-held surgical instrument available with a variety of end effectors including a hook, scissors, needle driver, and dissector offering 3 degrees of freedom and 360 degrees of rotation.
Key Points:
- The Canady Flex RoboWrist (Flex RoboWrist) is a fully articulating motorized, 5mm hand-held surgical instrument available with a variety of end effectors including a hook, scissors, needle driver, and dissector offering 3 degrees of freedom and 360 degrees of rotation.
- The device includes a connector for the USMI XL-1000 electrosurgical generator, which allows the option of using the mono scissors or hook for electrosurgery.
- Flex RoboWrist is equipped with state-of-the-art automation and intelligent control systems, optimizing surgical workflows, and saving valuable time in the operating room.
- The Canady Flex RoboWrist™ is also cost-effective, autoclavable up to 50 times and does not require the use of disposables.
Other Health,
Research,
General Health,
Oncology,
Medical Devices,
Clinical Trials,
Science,
Surgery,
Biotechnology,
Alternative Medicine,
FDA,
Health,
Anoxic waters,
DNA,
Radiation,
IRE,
Cell death,
RNS,
Safety,
CAP,
Survival,
Cancer,
Ovary,
Breast,
Global health,
Reactive nitrogen species,
Human embryonic stem cells clinical trials,
Prostate,
Treatment of lung cancer,
Immunotherapy,
CHCP,
Messenger,
Glioblastoma,
ASCO,
Irreversible electroporation,
ROS,
Sarcoma,
SMC,
Clinical trial,
LRR,
Patient,
Risk,
Melanoma,
Sheba Medical Center,
Plasma,
Annual general meeting,
Education minister,
IDE,
Rush University Medical Center,
RUMC,
Reactive oxygen species,
Society,
Medical imaging (ClinicalTrials.gov identifier: NCT04267575)
Key Points:
- (ClinicalTrials.gov identifier: NCT04267575)
Cancer remains a significant global health challenge, with over 1.9 million new cases and 608,570 cancer-related fatalities in the United States in 2021.
- USMI’s Canady Helios Cold Plasma (CHCP) system, a non-thermal (26-30°C) and non-contact Cold Atmospheric Plasma (CAP) jet, offers a promising solution.
- Twenty patients ranging from 26-85 years of age undergoing surgery for advanced stage 4 or recurrent solid tumors were enrolled.
- Patients with preoperative treatments such as neoadjuvant chemotherapy, immunotherapy, radiation, and previous surgery were eligible.
Retrieved on:
Wednesday, September 21, 2022
Research,
Surgery,
Medical Devices,
Clinical Trials,
Biotechnology,
Health,
General Health,
Science,
Oncology,
Safety,
Hip,
FDA,
LLC,
Electrosurgery,
Company,
Clinical trial,
CHCP,
Cancer,
CEO,
Medical Innovation Bill,
Innovation,
Plasma,
Medical device US Medical Innovations, LLC (USMI) , a subsidiary of US Patent Innovations, LLC, announced today it has secured a $10.2 million private placement deal from multiple sources including existing partners and new investors.
Key Points:
- US Medical Innovations, LLC (USMI) , a subsidiary of US Patent Innovations, LLC, announced today it has secured a $10.2 million private placement deal from multiple sources including existing partners and new investors.
- CEO Dr. Jerome Canady commented, We are pleased to have closed this round of private financing at such a critical time in our development efforts.
- Hybrid Plasma electrosurgery technology is used in more traditional surgeries such as hip and knee replacements.
- US Medical Innovations, LLC (USMI) is a private U.S. biomedical device company and wholly-owned subsidiary of US Patent Innovations, LLC.
Oncology,
Health,
Medical Devices,
Genetics,
Research,
Science,
Biotechnology,
Breast cancer,
TNBC,
MD,
Prognosis,
Academy of Technological Sciences of Ukraine,
Plasma,
Sirna,
LLC,
BCL2A1,
Growth hacking,
CHCP,
Scientific Reports,
Woman,
Cancer,
CELL,
Triple-negative breast cancer,
Cell death,
Pharmaceutical industry,
Vaccine,
Medical imaging,
JCRI-ABTS,
US Medical Innovations,
JCRI-ABTS,
US MEDICAL INNOVATIONS The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), announced today that their recent article, BCL2A1 REGULATES CANADY HELIOS COLD PLASMA-INDUCED CELL DEATH IN TRIPLE-NEGATIVE BREAST CANCER (TNBC) , has been published in Scientific Reports, a Nature Portfolio journal.
Key Points:
- The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), announced today that their recent article, BCL2A1 REGULATES CANADY HELIOS COLD PLASMA-INDUCED CELL DEATH IN TRIPLE-NEGATIVE BREAST CANCER (TNBC) , has been published in Scientific Reports, a Nature Portfolio journal.
- JCRI-ABTSs scientists demonstrated that a combination of Canady Helios Cold Plasma (CHCP) and anti-BCL2A1 treatment may be beneficial and a novel therapeutic option for triple-negative breast cancer and other solid tumor cancers.
- BCL2A1 expression plays an important role in cell survival after CHCP treatment in breast cancer cells and is potentially regulated by TNF-alpha.
- Silencing BCL2A1 by siRNA treatment or by downregulating its expression by CPI203 treatment in combination with CHCP significantly increases the potency of the CHCP treatment.
Retrieved on:
Thursday, September 2, 2021
Research,
Clinical Trials,
Biotechnology,
Health,
Pharmaceutical,
General Health,
Other Science,
Science,
Oncology,
LLC,
Apoptosis,
IDE,
Plasma,
News,
CHCP,
Canadian International Council,
Breast cancer,
Conference,
Sheba Medical Center,
Cancer,
Redox,
Cell death,
FDA,
Woman,
Research,
Cell cycle,
La Trobe Institute for Molecular Science,
CEO,
Academy of Technological Sciences of Ukraine,
Rush University Medical Center,
Clinical trial,
Cell proliferation,
International Journal of Molecular Sciences,
Pharmaceutical industry,
Medical imaging,
JCRI-ABTS,
US Medical Innovations,
JCRI-ABTS,
US MEDICAL INNOVATIONS The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), in collaboration with US Medical Innovations, LLC (USMI) , announced today that they have discovered the mechanism using Canady Helios Cold Plasma (CHCP) to induce cell death in breast cancer.
Key Points:
- The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), in collaboration with US Medical Innovations, LLC (USMI) , announced today that they have discovered the mechanism using Canady Helios Cold Plasma (CHCP) to induce cell death in breast cancer.
- Recently accepted for publication in the International Journal of Molecular Sciences, the article Canady Helios Cold Plasma Induces Breast Cancer Cell Death by Oxidation of Histone mRNA described how research scientists at JCRI/ABTS treated four (4) breast cancer cell lines with Canady Helios Cold Plasma (CHCP) at different dosages and monitored the progress of apoptosis (cell death).
- Inhibition of cell proliferation, induction of apoptosis, and disruption of cell cycle were all observed during the early S-phase of the cell cycle.
- JCRI-ABTS is a state-of-the-art BSL 2 translational molecular research laboratory focusing on Plasma Oncotherapeutics (a new cancer treatment modality) using Canady Helios Cold Plasma to investigate the potential of Cold Atmospheric Plasma to selectively treat cancer.
Research,
Medical devices,
Surgery,
FDA,
Biotechnology,
General Health,
Health,
Science,
Oncology,
Other Science,
Clinical medicine,
Medicine,
Medical specialties,
Surgical specialties,
Endoscopy,
Surgical oncology,
Laparoscopy b'US Medical Innovations, LLC (USMI) announced today that it is developing the first robotic delivery system used for cancer surgery.\nThe new Canady Surgical System (CSS) is a space-efficient, cost-effective, stand-alone solution for Robotic Assisted Surgery during open, laparoscopic/mini-invasive, endoscopic, thoracoscopic and trans-oral surgical procedures.\nFeatures of the new Canady Surgical System include Voice Command technology which frees up the surgeon and assistant to focus on the surgical procedure and perform other tasks.
Key Points:
- b'US Medical Innovations, LLC (USMI) announced today that it is developing the first robotic delivery system used for cancer surgery.\nThe new Canady Surgical System (CSS) is a space-efficient, cost-effective, stand-alone solution for Robotic Assisted Surgery during open, laparoscopic/mini-invasive, endoscopic, thoracoscopic and trans-oral surgical procedures.\nFeatures of the new Canady Surgical System include Voice Command technology which frees up the surgeon and assistant to focus on the surgical procedure and perform other tasks.
- We recently completed a Phase 1 FDA Clinical Trail using Canady Helios\xe2\x84\xa2 Cold Atmospheric Plasma (CHCAP) for the treatment of recurrent and stage 4 solid tumors .
- It is highly selective because it only targets cancer cells.
- And thirdly, the CHCAP treatment is personalized for specific cancer types (i.e., breast, ovarian, sarcoma, lung, colon, cervical, pancreas and other solid cancerous tumors).\nThe organization expects to have the new Canady Surgical System in clinical trials later this year.
Retrieved on:
Wednesday, April 28, 2021
Research,
Medical devices,
FDA,
Clinical trials,
Other Health,
Biotechnology,
General Health,
Health,
Science,
Oncology,
Cancer treatments,
Cancer,
Clinical medicine,
Chemotherapy regimens,
FOLFIRINOX,
FOLFIRI,
Chemotherapy,
7+3,
JCRI-ABTS,
US Medical Innovations,
JCRI-ABTS,
US MEDICAL INNOVATIONS Current treatments include systemic chemotherapeutic regimens such as FOLFIRINOX.
Key Points:
- Current treatments include systemic chemotherapeutic regimens such as FOLFIRINOX.
- A limitation of this chemotherapy regimen is its toxicity and adverse events.
- There exists a need for therapies to alleviate the toxicity of a FOLFIRINOX regimen while enhancing, or not altering, its anticancer properties.\nAccording to Jerome Canady, MD, and Chief Science Officer, \xe2\x80\x9cOur analysis of cell viability, proliferation, and the cell cycle demonstrated that CHCAP in combination with FOLFIRINOX is more effective than either treatment alone.
- USMI is dedicated to expanding the boundaries of plasma medicine by pioneering new technologies for the development of state-of-the-art medical devices that advance patient outcomes and improve human lives.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210428005762/en/\n'
